Last reviewed · How we verify
CSF-1 Component #1
CSF-1 Component #1 is a protein that modulates the activity of the colony-stimulating factor 1 receptor.
CSF-1 Component #1 is a protein that modulates the activity of the colony-stimulating factor 1 receptor. Used for Treatment of age-related macular degeneration.
At a glance
| Generic name | CSF-1 Component #1 |
|---|---|
| Sponsor | Orasis Pharmaceuticals Ltd. |
| Drug class | CSF-1 receptor modulator |
| Target | CSF-1R |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
CSF-1 Component #1 works by binding to the colony-stimulating factor 1 receptor, which is involved in the regulation of immune cells. This interaction can modulate the activity of these cells, potentially leading to therapeutic effects. However, the exact mechanism of action is not fully understood.
Approved indications
- Treatment of age-related macular degeneration
Common side effects
- Injection site reactions
Key clinical trials
- Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma (PHASE1, PHASE2)
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (PHASE1, PHASE2)
- Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (PHASE2)
- A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia (PHASE2)
- Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma (PHASE2)
- Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (PHASE2)
- Vaccine Therapy in Treating Patients With Stage IV Breast Cancer (PHASE1, PHASE2)
- Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |